Zacks Investment Research on MSN5d
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCCBristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...
GlobalData on MSN2d
Ono earmarks $940m to gain rare blood cancer therapy from IonisOno Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy by Ionis to treat polycythemia ...
Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...
Due to federal research cuts, Navy veteran Kyle Lewis says he won't be able to receive the cancer treatment that saved his ...
Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
The European Commission approved Opdivo plus Yervoy for first-line treatment of advanced liver cancer, citing significant ...
At one point, BMS said the facility would house 400 people. That was before Chairman and CEO Chris Boerner replaced Giovanni ...
The FDA’s Oncologic Drugs Advisory Committee recently voted to narrow the label for checkpoint inhibitors Keytruda and Opdivo ...
The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.
Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer. Bristol Myers on Friday ...
BMY is banking on new drugs to offset generic competition for older drugs. However, this might not be enough as the outlook ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback